Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CG Oncology, Inc.CGON · Entity 3735 | Director | June 04, 2026 | June 05, 2026 |
| Xilio Therapeutics, Inc.XLO · Entity 7122 | Director | June 11, 2025 | June 12, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CG Oncology, Inc.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.09 · Expires 2036-06-03 | Direct | 9,354 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 9,354 · Balance 9,354 F1: 1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date.
Xilio Therapeutics, Inc.
Report date June 11, 2025 · Filed June 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.69 · Expires 2035-06-10 | Direct | 31,000 |
Reported balance
After 2025-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-11 · Grant · Acquired 31,000 · Balance 31,000 F1: The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 11, 2025 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2026 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Blueprint Medicines Corp
Report date July 17, 2025 · Filed July 21, 2025
Section 16 reporting ended · disclosed 2025-07-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-07-17 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-07-17 · Grant · Acquired 39,456 · Balance 103,002 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F3: Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions ("PSUs"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award. Row 2 · 2025-07-17 · Disposition to issuer · Disposed 82,374 · Balance 20,628 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F3: Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions ("PSUs"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such RSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award. Row 3 · 2025-07-17 · Other · Disposed 20,628 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.75 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-07-17 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $86.60 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-07-17 · Disposition to issuer · Disposed 6,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $54.13 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-07-17 · Disposition to issuer · Disposed 28,500 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.13 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-07-17 · Disposition to issuer · Disposed 26,125 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.31 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-07-17 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.15 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-07-17 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $95.12 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-07-17 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $96.57 | Direct | 0 |
Reported balance
After 2025-07-17 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-07-17 · Disposition to issuer · Disposed 26,400 · Balance 0 F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser"). F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent. F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").
F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.
F3: Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions ("PSUs"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such RSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award.
F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration.
F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 03, 2021 Filed Mar 23, 2022 16:05 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 511 | $110.85 | $56,644.35 |
DisclosureSEC source: 0001415889-22-003280 · form4-03232022_040302.xml · nonDerivative · entry 1 Rossi Christina · CIK 0001756941 · CHIEF COMMERCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,968 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · balance_after: The amount of securities beneficially owned by the Reporting Person, as reported in Forms 4 filed by the Reporting Person subsequent to the Transaction Date but prior to the date of this Form 4, did not reflect this sell to cover transaction. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 17:48 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 1,272 | $86.61 | $110,167.92 |
DisclosureSEC source: 0001179110-21-003005 · edgar.xml · nonDerivative · entry 2 Rossi Christina · CIK 0001756941 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,723 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 17:48 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 87 | $89.10 | $7,751.70 |
DisclosureSEC source: 0001179110-21-003005 · edgar.xml · nonDerivative · entry 1 Rossi Christina · CIK 0001756941 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,995 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.08 to $89.25 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 16:27 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantStock Option (Right to Buy) · Derivative | 26,125 | $0.00 Strike: $100.13 | $0.00 |
DisclosureSEC source: 0001179110-21-002672 · edgar.xml · derivative · entry 2 Rossi Christina · CIK 0001756941 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,125 Underlying: Common Stock · 26,125 shares Expires 2031-03-01 F2 · derivative.exercise_date: This option vests with respect to 1/48th of the shares underlying the option on April 1, 2021 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 16:27 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantCommon Stock | 13,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002672 · edgar.xml · nonDerivative · entry 1 Rossi Christina · CIK 0001756941 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,082 F1 · balance_after: The reported transaction involved the Reporting Person's receipt of a grant of 13,062 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 17:02 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 345 | $99.69 | $34,393.05 |
DisclosureSEC source: 0001179110-20-010844 · edgar.xml · nonDerivative · entry 1 Rossi Christina · CIK 0001756941 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,020 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 16:27 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | SaleCommon Stock | 135 | $51.96 | $7,014.60 |
DisclosureSEC source: 0001179110-20-003468 · edgar.xml · nonDerivative · entry 1 Rossi Christina · CIK 0001756941 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,365 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 19:11 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantStock Option (Right to Buy) · Derivative | 28,500 | $0.00 Strike: $54.13 | $0.00 |
DisclosureSEC source: 0001179110-20-002965 · edgar.xml · derivative · entry 2 Rossi Christina · CIK 0001756941 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,500 Underlying: Common Stock · 28,500 shares Expires 2030-03-01 F2 · derivative.exercise_date: This option vests with respect to 1/48th of the shares underlying the option on April 1, 2020 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document |
| March 01, 2020 Filed Mar 3, 2020 19:11 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantCommon Stock | 14,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002965 · edgar.xml · nonDerivative · entry 1 Rossi Christina · CIK 0001756941 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,500 F1 · balance_after: The reported transaction involved the Reporting Person's receipt of a grant of 14,250 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan. The Reporting Person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 includes the 14,250 newly awarded restricted stock units, 5,125 previously reported restricted stock units, 438 of which vested on March 1, 2020, and 1,125 shares of common stock. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 16:16 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Exercise / conversionRestricted Stock Units · Derivative | 1,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-011412 · edgar.xml · derivative · entry 2 Rossi Christina · CIK 0001756941 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,375 Underlying: Common Stock · 1,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On November 1, 2018, the reporting person was granted 4,500 restricted stock units, vesting in four equal annual installments on November 1, 2019, 2020, 2021 and 2022. F2 · derivative.expiration_date: On November 1, 2018, the reporting person was granted 4,500 restricted stock units, vesting in four equal annual installments on November 1, 2019, 2020, 2021 and 2022. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 16:16 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | Exercise / conversionCommon Stock | 1,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-19-011412 · edgar.xml · nonDerivative · entry 1 Rossi Christina · CIK 0001756941 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 17:24 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantRestricted Stock Units · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-003306 · edgar.xml · derivative · entry 2 Rossi Christina · CIK 0001756941 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750 Underlying: Common Stock · 1,750 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments on March 1, 2020, 2021, 2022 and 2023. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments on March 1, 2020, 2021, 2022 and 2023. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 17:24 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $86.60 | $0.00 |
DisclosureSEC source: 0001179110-19-003306 · edgar.xml · derivative · entry 1 Rossi Christina · CIK 0001756941 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2029-03-01 F1 · derivative.exercise_date: This option vests with respect to 1/48th of the shares underlying the option on April 1, 2019 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 16:55 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantRestricted Stock Units · Derivative | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-012562 · edgar.xml · derivative · entry 2 Rossi Christina · CIK 0001756941 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments on November 1, 2019, 2020, 2021 and 2022. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments on November 1, 2019, 2020, 2021 and 2022. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 16:55 UTC | Blueprint Medicines Corp BPMC · Entity 77326 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $65.75 | $0.00 |
DisclosureSEC source: 0001179110-18-012562 · edgar.xml · derivative · entry 1 Rossi Christina · CIK 0001756941 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2028-11-01 F1 · date: In accordance with the Issuer's equity award grant policy, this option was granted effective as of the first day of the month following the commencement of the Reporting Person's employment with the Issuer on October 29, 2018. F2 · derivative.exercise_date: This option vests with respect to 25% of the shares underlying the option on November 1, 2019 and as to an additional 1/48th of the shares underlying the option each month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.